Formulary guidance and transparency from P&T to point of care


Reality Check on Opioid Dependence

Market access for opioid dependence treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 53% of the lives under commercial formularies are covered without utilization management restrictions
  • Class Trends: In April 2019, the FDA approved Teva Pharmaceuticals’ generic naloxone nasal spray, an equivalent to Emergent BioSolutions’ Narcan, which can be used to reverse opioid overdoses
  • Key Findings: Buprenorphine and naloxone combination products compete for position given their relative clinical parity and functionality. Indivior PLC’s Suboxone has been the most favorable brand, and it now competes with BioDelivery Sciences International, Inc.’s Bunavail and Orexo US, Inc.’s Zubsolv

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.